At the 44th Annual Meeting of the Infectious Diseases Society of America (IDSA), held this year in (Toronto, Ontario), for the first time Advanced Life Sciences Holdings, Inc. (Nasdaq: ADLS) has presented the clinical results comparing the safety and efficacy of cethromycin at varying doses for the treatment of acute bacterial sinusitis (ABS).
The following posters were presented:
Details of the double-blind, randomized, parallel-group, muti-center study comparing cethromycin 150 mg QD, cethromycin 300 mg QD and cethromycin 600 mg QD, all for ten days, for the treatment of ABS, where the clinical and bacteriological cure rates were found generally greater in the 300 mg QD group than in both the 150 mg and 600 mg QD groups.
A study on the safety and efficacy of a ten day course of cethromycin given either 150 mg QD or 150 mg BID in subjects with ABS. where it was demonstrated that both treatment regimens were effective in resolving or improving clinical signs and symptoms of ABS and eradicating the target pathogens in adult subjects.
Cethromycin is Advanced Life Sciences Holdings, Inc.'s lead product candidate, a novel ketolide antibiotic in late-stage clinical development for the treatment of respiratory tract infections.
Find more details of the clincial results from the press release.
Comment Preview